Smith & Nephew plc (LON:SN) Receives GBX 1,381.33 Average Target Price from Analysts

Shares of Smith & Nephew plc (LON:SN) have been assigned an average rating of “Hold” from the six brokerages that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is GBX 1,381.33.

SN has been the topic of several analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,350 target price on shares of Smith & Nephew in a report on Tuesday, March 17th. Berenberg Bank reiterated a “hold” rating and set a GBX 1,300 target price on shares of Smith & Nephew in a report on Friday, January 23rd.

Smith & Nephew Stock Performance

SN opened at GBX 1,214.50 on Friday. The company has a market capitalization of £13.31 billion, a price-to-earnings ratio of 43.73, a PEG ratio of 0.46 and a beta of 0.74. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90. The stock’s 50-day moving average is GBX 1,258.89 and its 200-day moving average is GBX 1,267.76.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.